BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Jae Jin Lee, Martine Extermann. Cancer and Chronic Conditions2016; : 131 doi: 10.1007/978-981-10-1844-2_5
2
G. de Stefano, V. Iodice, N. Farella. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case ReportJournal of Gastrointestinal Cancer 2015; 46(4): 430 doi: 10.1007/s12029-015-9720-5
3
Stefano Colagrande, Francesco Regini, Gian Giacomo Taliani, Cosimo Nardi, Andrea Lorenzo Inghilesi. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-upWorld Journal of Hepatology 2015; 7(8): 1041-1053 doi: 10.4254/wjh.v7.i8.1041
4
Xue-Fen Lei, Yang Ke, Tian-Hao Bao, Hao-Ran Tang, Xue-Song Wu, Zhi-Tian Shi, Jie Lin, Zhi-Xian Zhang, Hou Gu, Lin Wang. Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative studyWorld Journal of Clinical Cases 2018; 6(5): 74-83 doi: 10.12998/wjcc.v6.i5.74
5
Gennaro Gadaleta-Caldarola, Stefania Infusino, Rosa Divella, Emanuela Ferraro, Antonio Mazzocca, Ferruccio De Rose, Gianfranco Filippelli, Ines Abbate, Mario Brandi. Sorafenib: 10 years after the first pivotal trialFuture Oncology 2015; 11(13): 1863 doi: 10.2217/fon.15.85
6
Thomas Reiberger, Yunching Chen, Rakesh R Ramjiawan, Tai Hato, Christopher Fan, Rekha Samuel, Sylvie Roberge, Peigen Huang, Gregory Y Lauwers, Andrew X Zhu, Nabeel Bardeesy, Rakesh K Jain, Dan G Duda. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosisNature Protocols 2015; 10(8): 1264 doi: 10.1038/nprot.2015.080
7
Yadi Liao, Yun Zheng, Wei He, Qijiong Li, Jingxian Shen, Jian Hong, Ruhai Zou, Jiliang Qiu, Binkui Li, Yunfei Yuan. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrenceOncology Letters 2017; 13(2): 984 doi: 10.3892/ol.2016.5525
8
Seong K. Na, Sun Y. Yim, Sang J. Suh, Young K. Jung, Ji H. Kim, Yeon S. Seo, Hyung J. Yim, Jong E. Yeon, Kwan S. Byun, Soon H. Um. ALBI versus Child-Pugh grading systems for liver function in patients with hepatocellular carcinomaJournal of Surgical Oncology 2018; 117(5): 912 doi: 10.1002/jso.24992
9
Ming‐Lun Yeh, Chung‐Feng Huang, Ching‐I Huang, Ming‐Yen Hsieh, Nei‐Jen Hou, I‐Hung Lin, Po‐Cheng Liang, Yi‐Shan Tsai, Meng‐Hsuan Hsieh, Zu‐Yau Lin, Shinn‐Chern Chen, Chia‐Yen Dai, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatmentThe Kaohsiung Journal of Medical Sciences 2019; 35(10): 624 doi: 10.1002/kjm2.12105
10
Wen-Tsan Chang, Sheng-Nan Lu, Kung-Ming Rau, Ching-Shan Huang, King-Teh Lee. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patientsThe Kaohsiung Journal of Medical Sciences 2018; 34(7): 391 doi: 10.1016/j.kjms.2018.03.006
11
Brittany Dewdney, Alexandra Roberts, Liang Qiao, Jacob George, Lionel Hebbard. A Sweet Connection? Fructose’s Role in Hepatocellular CarcinomaBiomolecules 2020; 10(4): 496 doi: 10.3390/biom10040496
12
Sae Hwan Lee, Il Han Song, Ran Noh, Ha Yan Kang, Suk Bae Kim, Soon Young Ko, Eoum Seok Lee, Seok Hyun Kim, Byung Seok Lee, An Na Kim, Hee Bok Chae, Hong Soo Kim, Tae Hee Lee, Young Woo Kang, Jae Dong Lee, Heon Young Lee. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutionsBMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1273-2
13
Haruhiko Takeda, Hiroki Nishikawa, Yukio Osaki, Kaoru Tsuchiya, Kouji Joko, Chikara Ogawa, Hiroyoshi Taniguchi, Etsuro Orito, Yasushi Uchida, Namiki Izumi. Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinomaHepatology Research 2015; 45(10): E130 doi: 10.1111/hepr.12480
14
Xuying Wan, Xiaofeng Zhai, Zhenlin Yan, Pinghua Yang, Jun Li, Dong Wu, Kui Wang, Yong Xia, Feng Shen. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinomaOncotarget 2016; 7(50): 83806 doi: 10.18632/oncotarget.11514